IRIS Accounts Production v24.3.2.46 03201556 Board of Directors 1.7.23 30.6.24 30.6.24 Manufacture of basic pharmaceutical products. true false true true false false true true true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh032015562023-06-30032015562024-06-30032015562023-07-012024-06-30032015562022-06-30032015562022-07-012023-06-30032015562023-06-3003201556ns15:EnglandWales2023-07-012024-06-3003201556ns14:PoundSterling2023-07-012024-06-3003201556ns10:Director12023-07-012024-06-3003201556ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3003201556ns10:FRS1022023-07-012024-06-3003201556ns10:Audited2023-07-012024-06-3003201556ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport2023-07-012024-06-3003201556ns10:LargeMedium-sizedCompaniesRegimeForAccounts2023-07-012024-06-3003201556ns10:FullAccounts2023-07-012024-06-3003201556ns10:OrdinaryShareClass12023-07-012024-06-3003201556ns10:Director22023-07-012024-06-3003201556ns10:RegisteredOffice2023-07-012024-06-3003201556ns5:CurrentFinancialInstruments2024-06-3003201556ns5:CurrentFinancialInstruments2023-06-3003201556ns5:Non-currentFinancialInstruments2024-06-3003201556ns5:Non-currentFinancialInstruments2023-06-3003201556ns5:ShareCapital2024-06-3003201556ns5:ShareCapital2023-06-3003201556ns5:SharePremium2024-06-3003201556ns5:SharePremium2023-06-3003201556ns5:RetainedEarningsAccumulatedLosses2024-06-3003201556ns5:RetainedEarningsAccumulatedLosses2023-06-3003201556ns5:ShareCapital2022-06-3003201556ns5:RetainedEarningsAccumulatedLosses2022-06-3003201556ns5:SharePremium2022-06-3003201556ns5:RetainedEarningsAccumulatedLosses2022-07-012023-06-3003201556ns5:RetainedEarningsAccumulatedLosses2023-07-012024-06-3003201556ns5:ShortLeaseholdAssetsns5:LandBuildings2023-07-012024-06-3003201556ns5:PlantMachinery2023-07-012024-06-3003201556ns5:FurnitureFittings2023-07-012024-06-3003201556ns5:MotorVehicles2023-07-012024-06-3003201556ns15:UnitedKingdom2023-07-012024-06-3003201556ns15:UnitedKingdom2022-07-012023-06-3003201556ns15:Europe2023-07-012024-06-3003201556ns15:Europe2022-07-012023-06-3003201556ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-07-012024-06-3003201556ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2022-07-012023-06-3003201556ns10:HighestPaidDirector2023-07-012024-06-3003201556ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2023-07-012024-06-3003201556ns5:PlantEquipmentOtherAssetsUnderOperatingLeases2022-07-012023-06-3003201556ns5:OwnedAssets2023-07-012024-06-3003201556ns5:OwnedAssets2022-07-012023-06-3003201556ns5:FinanceLeases2023-07-012024-06-3003201556ns5:FinanceLeases2022-07-012023-06-3003201556ns10:OrdinaryShareClass12022-07-012023-06-3003201556ns5:ShortLeaseholdAssetsns5:LandBuildings2023-06-3003201556ns5:PlantMachinery2023-06-3003201556ns5:FurnitureFittings2023-06-3003201556ns5:ShortLeaseholdAssetsns5:LandBuildings2024-06-3003201556ns5:PlantMachinery2024-06-3003201556ns5:FurnitureFittings2024-06-3003201556ns5:ShortLeaseholdAssetsns5:LandBuildings2023-06-3003201556ns5:PlantMachinery2023-06-3003201556ns5:FurnitureFittings2023-06-3003201556ns5:MotorVehicles2023-06-3003201556ns5:ComputerEquipment2023-06-3003201556ns5:ComputerEquipment2023-07-012024-06-3003201556ns5:MotorVehicles2024-06-3003201556ns5:ComputerEquipment2024-06-3003201556ns5:MotorVehicles2023-06-3003201556ns5:ComputerEquipment2023-06-3003201556ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-06-3003201556ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-06-3003201556ns5:WithinOneYear2024-06-3003201556ns5:WithinOneYear2023-06-3003201556ns5:BetweenOneFiveYears2024-06-3003201556ns5:BetweenOneFiveYears2023-06-3003201556ns5:MoreThanFiveYears2024-06-3003201556ns5:MoreThanFiveYears2023-06-3003201556ns5:AllPeriods2024-06-3003201556ns5:AllPeriods2023-06-3003201556ns5:DeferredTaxation2023-06-3003201556ns5:OtherProvisionsContingentLiabilities2023-06-3003201556ns5:DeferredTaxation2023-07-012024-06-3003201556ns5:OtherProvisionsContingentLiabilities2023-07-012024-06-3003201556ns5:DeferredTaxation2024-06-3003201556ns5:OtherProvisionsContingentLiabilities2024-06-3003201556ns10:OrdinaryShareClass12024-06-3003201556ns5:RetainedEarningsAccumulatedLosses2023-06-3003201556ns5:SharePremium2023-06-30
REGISTERED NUMBER: 03201556 (England and Wales)















Strategic Report, Report of the Directors and

Financial Statements for the Year Ended 30 June 2024

for

Pharmapac (U.K.) Limited

Pharmapac (U.K.) Limited (Registered number: 03201556)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 4

Income Statement 7

Other Comprehensive Income 8

Balance Sheet 9

Statement of Changes in Equity 10

Notes to the Financial Statements 11


Pharmapac (U.K.) Limited

Company Information
for the Year Ended 30 June 2024







DIRECTORS: G Elliott
J J Pugh





REGISTERED OFFICE: Unit 22
Valley Road Business Park
Bidston
Wirral
CH41 7EL





REGISTERED NUMBER: 03201556 (England and Wales)





AUDITORS: WHR Accountants Ltd
Chartered Certified Accountants
Statutory Auditors
56 English Street
Armagh
Co. Armagh
BT61 7LG

Pharmapac (U.K.) Limited (Registered number: 03201556)

Strategic Report
for the Year Ended 30 June 2024

The directors present their strategic report for the year ended 30 June 2024.

REVIEW OF BUSINESS
Pharmapac (UK) Limited's principal activities during the year only reflect the core business of packaging of Pharmaceutical products as the business has transferred it's consumer health business to a new company, Vector Consumer Limited. The prior year figures have been adjusted accordingly to reflect the change.

The key financial and other performance indicators during the year were as follows:

2024 2023
Turnover £12,152,483 £8,063,251
GP % 31% 29%
NP% 4% 6%
PAT % 2% 1%
Current Ratio 2.50:1 2.93:1

Investment in new plant and machinery has significantly increased turnover with profit margins remaining stable. The Directors, while accepting of this performance are working hard to deliver efficiencies and improve productivity in the business.


The business has continued its investment in staff and facilities in order to meet new customer demand and the development of new production processes.

Looking forward to the 2024/25 trading year the Directors are confident that the business is well placed to take advantage of the new business opportunities that the market now offers.

PRINCIPAL RISKS AND UNCERTAINTIES
Price risk
The company is exposed to price pressure through competition in the market, this risk could result in loss of revenue. The company actively manages the risk by providing leading products and services to its customers. The company operates lean manufacturing processes and flexible production techniques in order to exceed customer expectations for products and services, therefore maintaining strong relationships.

Liquidity risk
The company manages financial risk by monitoring cashflow to ensure that the company is able to meet its foreseeable debts as they fall due.

Financial instrument risk
The company has established a risk and financial management framework whose primary objectives are to protect the company from events that hinder the achievement of the company's performance objectives. The objectives aim to limit undue counterparty exposure, ensure sufficient working capital exists and monitor the management of risk at a business unit level.

Environmental
The directors recognise the importance of the company's environmental responsibilities. The company monitors its impact on the environment, and designs and implements policies to mitigate any adverse impact that might be caused by its activities. These include the safe disposal of manufacturing waste, recycling and reduction of energy consumption.

Employees
Details of the number of employees and related costs can be found in notes within the financial statements.

ON BEHALF OF THE BOARD:





G Elliott - Director


24 February 2025

Pharmapac (U.K.) Limited (Registered number: 03201556)

Report of the Directors
for the Year Ended 30 June 2024

The directors present their report with the financial statements of the company for the year ended 30 June 2024.

DIVIDENDS
No dividends will be distributed for the year ended 30 June 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 July 2023 to the date of this report.

G Elliott
J J Pugh

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, WHR Accountants Ltd, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





G Elliott - Director


24 February 2025

Report of the Independent Auditors to the Members of
Pharmapac (U.K.) Limited

Opinion
We have audited the financial statements of Pharmapac (U.K.) Limited (the 'company') for the year ended 30 June 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 30 June 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Members of
Pharmapac (U.K.) Limited


Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, and instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

-the Company's own assessment of the risk that irregularities may occur either as a result of fraud or error;
-the results of our enquiries of management about their own identification and assessment of the risks of irregularities;
-any matters we identified having obtained and reviewed the Company's documentation of their policies and procedures relating to:
identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud; and
the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations; and
-the matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

In addition to the above, our procedures to respond to risks identified included the following:
-reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
-enquiring of management, directors concerning actual and potential litigation and claims;
-performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
-reading minutes of meeting of directors, reviewing internal audit reports and reviewing correspondence with HMRC; and
-in addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments;
-assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and
-evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occuring due to fraud rather than error, as fraud involves intentional concealment,forgery,collusion,omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Pharmapac (U.K.) Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




James Robinson (Senior Statutory Auditor)
for and on behalf of WHR Accountants Ltd
Chartered Certified Accountants
Statutory Auditors
56 English Street
Armagh
Co. Armagh
BT61 7LG

24 February 2025

Pharmapac (U.K.) Limited (Registered number: 03201556)

Income Statement
for the Year Ended 30 June 2024

30.6.24 30.6.23
as restated
Notes £    £   

TURNOVER 3 12,152,483 8,063,251

Cost of sales 8,431,981 5,677,986
GROSS PROFIT 3,720,502 2,385,265

Administrative expenses 3,174,284 1,968,060
546,218 417,205

Other operating income 4 - 182,342
OPERATING PROFIT 6 546,218 599,547


Interest payable and similar expenses 7 4,926 109,472
PROFIT BEFORE TAXATION 541,292 490,075

Tax on profit 8 321,975 382,560
PROFIT FOR THE FINANCIAL YEAR 219,317 107,515

Pharmapac (U.K.) Limited (Registered number: 03201556)

Other Comprehensive Income
for the Year Ended 30 June 2024

30.6.24 30.6.23
as restated
Notes £    £   

PROFIT FOR THE YEAR 219,317 107,515


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR THE YEAR 219,317 107,515

Pharmapac (U.K.) Limited (Registered number: 03201556)

Balance Sheet
30 June 2024

30.6.24 30.6.23
as restated
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 11 5,793,311 5,127,296

CURRENT ASSETS
Stocks 12 1,166,149 1,398,067
Debtors 13 5,471,908 5,700,411
Cash at bank and in hand 446,864 780,563
7,084,921 7,879,041
CREDITORS
Amounts falling due within one year 14 2,829,994 2,689,519
NET CURRENT ASSETS 4,254,927 5,189,522
TOTAL ASSETS LESS CURRENT LIABILITIES 10,048,238 10,316,818

CREDITORS
Amounts falling due after more than one year 15 (1,244,967 ) (2,054,839 )

PROVISIONS FOR LIABILITIES 17 (674,554 ) (352,579 )
NET ASSETS 8,128,717 7,909,400

CAPITAL AND RESERVES
Called up share capital 18 114,865 114,865
Share premium 19 516,136 516,136
Retained earnings 19 7,497,716 7,278,399
SHAREHOLDERS' FUNDS 8,128,717 7,909,400

The financial statements were approved by the Board of Directors and authorised for issue on 24 February 2025 and were signed on its behalf by:





G Elliott - Director


Pharmapac (U.K.) Limited (Registered number: 03201556)

Statement of Changes in Equity
for the Year Ended 30 June 2024

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1 July 2022 114,865 10,170,884 516,136 10,801,885

Changes in equity
Dividends - (3,000,000 ) - (3,000,000 )
Total comprehensive income - 107,515 - 107,515
Balance at 30 June 2023 114,865 7,278,399 516,136 7,909,400

Changes in equity
Total comprehensive income - 219,317 - 219,317
Balance at 30 June 2024 114,865 7,497,716 516,136 8,128,717

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Pharmapac (U.K.) Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows;
the requirements of paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
the requirement of paragraph 33.7.

The financial statements are consolidated into the financial statements of Pharmapac Holdings Limited which can be obtained from Companies House.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Short leasehold - 10% on cost
Plant and machinery - at varying rates on cost
Fixtures and fittings - 20% on cost
Motor vehicles - 20% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Raw materials, consumables and goods for resale - purchase cost on a first-in, firstout basis

Work in progress and finished goods - cost of direct materials and labour plus attributable overheads based on a normal level of activity.

Net realisable value is based on estimated selling price less any further costs expected to be incurred to completion and disposal.

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Debt instruments are subsequently measured at amortised cost.
Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit of loss.
All other such investments are subsequently measured at cost less impairment.
Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.
Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.
Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

2. ACCOUNTING POLICIES - continued

Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.
When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.

Leased assets
For any new contracts entered into on or after 1 January 2019, the company considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period in exchange for consideration'. To apply this definition the company assesses whether the contract meets three key evaluations which are whether:
* the contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the company
* the company has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract
the company has the right to direct the use of the identified asset throughout the period of use. The company assess whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use.
Measurement and recognition of leases as a lessee
At lease commencement date, the company recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the company, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received).
The company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The company also assesses the right-of-use asset for impairment when such indicators exist.
At the commencement date, the company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the company's incremental borrowing rate.
Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments.
When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero.
The company has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term.
On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in trade and other payables.

3. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

30.6.24 30.6.23
as restated
£    £   
United Kingdom 11,177,007 7,499,302
Europe 975,476 563,949
12,152,483 8,063,251

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

4. OTHER OPERATING INCOME
30.6.24 30.6.23
as restated
£    £   
Sundry receipts - 181,000
Government grants - 1,342
- 182,342

5. EMPLOYEES AND DIRECTORS
30.6.24 30.6.23
as restated
£    £   
Wages and salaries 4,655,225 2,870,933
Social security costs 397,171 319,803
5,052,396 3,190,736

The average number of employees during the year was as follows:
30.6.24 30.6.23
as restated

Production staff 140 104
Administrative staff 10 29
150 133

During the year the company paid £80,779 towards employer pension costs.

30.6.24 30.6.23
as restated
£    £   
Directors' remuneration 229,531 151,341

Information regarding the highest paid director for the year ended 30 June 2024 is as follows:
30.6.24

£   
Emoluments etc 229,531

6. OPERATING PROFIT

The operating profit is stated after charging:

30.6.24 30.6.23
as restated
£    £   
Hire of plant and machinery 186,553 133,009
Other operating leases 36,124 31,770
Depreciation - owned assets 1,019,014 840,618
Loss on disposal of fixed assets 647 29,637
Auditors' remuneration 34,515 36,297

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

7. INTEREST PAYABLE AND SIMILAR EXPENSES
30.6.24 30.6.23
as restated
£    £   
Leasing 4,926 109,472

8. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
30.6.24 30.6.23
as restated
£    £   
Current tax:
UK corporation tax - 317,914

Deferred tax 321,975 64,646
Tax on profit 321,975 382,560

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

30.6.24 30.6.23
as restated
£    £   
Profit before tax 541,292 490,075
Profit multiplied by the standard rate of corporation tax in the UK of 25% (2023 -
20.496%)

135,323

100,446

Effects of:
Expenses not deductible for tax purposes 4,114 7,924
Capital allowances in excess of depreciation (139,437 ) (154,397 )
Amortisation of capital grant - (275 )
Deduction for R & D expenditure claim - (134,400 )
Deferred tax movement 321,975 64,646
Adjustments to tax charge - 498,616
Total tax charge 321,975 382,560

9. DIVIDENDS
30.6.24 30.6.23
as restated
£    £   
Ordinary shares of 1 each
Final - 3,000,000

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

10. PRIOR YEAR ADJUSTMENT

The comparative figures have been restated to incorporate the impact of hiving out the business Vector Consumer at 1st July 2023. The change has resulted in no reduction in Reserves available for distribution at 1st July 2023 and a nil effect on the Balance Sheet.


Summary of prior year accounting impact£
Reduction in Turnover8,400,829
Reduction in Cost of Sales(5,062,112)
Reduction in Administrative expenses(914,966)
Reduction in Other Operating Income9,000
Reduction in Current Assets(1,579,111)
Reduction in Current Liabilities1,579,111


11. TANGIBLE FIXED ASSETS
Fixtures
Short Plant and and
leasehold machinery fittings
£    £    £   
COST
At 1 July 2023 1,143,373 4,892,728 729,147
Additions 78,719 1,947,024 35,394
Disposals - (57,392 ) (9,120 )
At 30 June 2024 1,222,092 6,782,360 755,421
DEPRECIATION
At 1 July 2023 724,336 2,503,396 598,680
Charge for year 86,619 479,382 53,140
Eliminated on disposal - (31,267 ) (9,120 )
At 30 June 2024 810,955 2,951,511 642,700
NET BOOK VALUE
At 30 June 2024 411,137 3,830,849 112,721
At 30 June 2023 419,037 2,389,332 130,467

Motor Right to
vehicles use Totals
£    £    £   
COST
At 1 July 2023 11,995 3,368,778 10,146,021
Additions - 640,665 2,701,802
Disposals - (1,886,948 ) (1,953,460 )
At 30 June 2024 11,995 2,122,495 10,894,363
DEPRECIATION
At 1 July 2023 11,995 1,180,318 5,018,725
Charge for year - 399,873 1,019,014
Eliminated on disposal - (896,300 ) (936,687 )
At 30 June 2024 11,995 683,891 5,101,052
NET BOOK VALUE
At 30 June 2024 - 1,438,604 5,793,311
At 30 June 2023 - 2,188,460 5,127,296

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

12. STOCKS
30.6.24 30.6.23
as restated
£    £   
Stocks 1,166,149 1,398,067

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
as restated
£    £   
Trade debtors 3,467,481 5,209,447
Amounts owed by group undertakings 1,503,804 -
Other debtors 116,269 135,205
Prepayments 384,354 355,759
5,471,908 5,700,411

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
as restated
£    £   
Trade creditors 2,177,652 1,551,383
Tax (276,624 ) 7,376
Social security and other taxes 115,055 86,061
VAT 291,964 19,610
Other creditors 18,859 13,462
Derivative financial liability 222,219 339,799
Accruals 280,869 671,828
2,829,994 2,689,519

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
30.6.24 30.6.23
as restated
£    £   
Derivative financial liability 1,244,967 2,054,839

16. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
30.6.24 30.6.23
as restated
£    £   
Within one year 222,219 339,799
Between one and five years 901,955 1,494,469
In more than five years 343,011 560,371
1,467,185 2,394,639

17. PROVISIONS FOR LIABILITIES
30.6.24 30.6.23
as restated
£    £   
Deferred tax 674,554 352,579

Pharmapac (U.K.) Limited (Registered number: 03201556)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

17. PROVISIONS FOR LIABILITIES - continued

Deferred Government
tax Grants
£    £   
Balance at 1 July 2023 352,579 -
Charge to Income Statement during year 321,975 -
Balance at 30 June 2024 674,554 -

The amounts recognised in the financial statements for government grants are as follows:


30.06.24
30.06.23as
restated
£ £
Recognised in creditors:
Deferred government grants due within one year--

Recognised in other operating income:
Government grants recognised directly in income-1,342

18. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.6.24 30.6.23
value: as restated
£    £   
114,865 Ordinary 1 114,865 114,865

19. RESERVES
Retained Share
earnings premium Totals
£    £    £   

At 1 July 2023 7,278,399 516,136 7,794,535
Profit for the year 219,317 219,317
At 30 June 2024 7,497,716 516,136 8,013,852

20. RELATED PARTY DISCLOSURES

During the year the company entered into the following transactions with related parties:



Transaction value

Balance owed
by/(owed to

)

2023 2023 2024 2023
£    £    £    £   
Hilmark Ltd (120,000 ) (120,000 ) (6,000 ) (6,000 )

These transactions consisted of management charges paid to the related parties for services rendered during the year.

21. ULTIMATE CONTROLLING PARTY

At the balance sheet date Pharmapac Holdings Ltd was the ultimate company, holding 100% of the issued share capital. In the opinion of the directors there was no ultimate controlling party at the balance sheet date.
Pharmapac Holdings Ltd is incorporated in Northern Ireland.